Morgan Stanley’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,448
| Closed | -$13.7K | – | 8129 |
|
|
2025
Q1 | $13.7K | Sell |
1,448
-2,153
| -60% | -$25.1K | ﹤0.01% | 6706 |
|
|
2024
Q4 | $44.3K | Sell |
3,601
-1,443
| -29% | -$20.4K | ﹤0.01% | 6324 |
|
|
2024
Q3 | $75.4K | Sell |
5,044
-15,272
| -75% | -$225K | ﹤0.01% | 6100 |
|
|
2024
Q2 | $274K | Buy |
20,316
+1,063
| +6% | +$15.7K | ﹤0.01% | 5542 |
|
|
2024
Q1 | $320K | Sell |
19,253
-7,449
| -28% | -$115K | ﹤0.01% | 5526 |
|
|
2023
Q4 | $360K | Buy |
26,702
+23,190
| +660% | +$253K | ﹤0.01% | 5741 |
|
|
2023
Q3 | $38.5K | Hold |
3,512
| – | – | ﹤0.01% | 6274 |
|
|
2023
Q2 | $45.4K | Sell |
3,512
-525
| -13% | -$6.88K | ﹤0.01% | 6244 |
|
|
2023
Q1 | $48.4K | Sell |
4,037
-860
| -18% | -$11.7K | ﹤0.01% | 6299 |
|
|
2022
Q4 | $67.2K | Hold |
4,897
| – | – | ﹤0.01% | 6156 |
|
|
2022
Q3 | $72K | Hold |
4,897
| – | – | ﹤0.01% | 6233 |
|
|
2022
Q2 | $74K | Sell |
4,897
-845
| -15% | -$13K | ﹤0.01% | 6420 |
|
|
2022
Q1 | $104K | Buy |
5,742
+1,029
| +22% | +$19.5K | ﹤0.01% | 6278 |
|
|
2021
Q4 | $112K | Sell |
4,713
-1,667
| -26% | -$46.3K | ﹤0.01% | 6368 |
|
|
2021
Q3 | $193K | Hold |
6,380
| – | – | ﹤0.01% | 6018 |
|
|
2021
Q2 | $203K | Buy |
6,380
+2,434
| +62% | +$73.4K | ﹤0.01% | 6009 |
|
|
2021
Q1 | $118K | Buy |
3,946
+188
| +5% | +$6.12K | ﹤0.01% | 5921 |
|
|
2020
Q4 | $119K | Sell |
3,758
-897
| -19% | -$26.9K | ﹤0.01% | 5838 |
|
|
2020
Q3 | $127K | Buy |
4,655
+400
| +9% | +$10.7K | ﹤0.01% | 5316 |
|
|
2020
Q2 | $115K | Sell |
4,255
-6,350
| -60% | -$156K | ﹤0.01% | 5336 |
|
|
2020
Q1 | $207K | Sell |
10,605
-32,520
| -75% | -$701K | ﹤0.01% | 4848 |
|
|
2019
Q4 | $1.01M | Buy |
43,125
+2,659
| +7% | +$56.3K | ﹤0.01% | 4521 |
|
|
2019
Q3 | $759K | Buy |
40,466
+31,261
| +340% | +$635K | ﹤0.01% | 4462 |
|
|
2019
Q2 | $194K | Hold |
9,205
| – | – | ﹤0.01% | 5036 |
|
|
2019
Q1 | $193K | Sell |
9,205
-36,315
| -80% | -$762K | ﹤0.01% | 5083 |
|
|
2018
Q4 | $859K | Sell |
45,520
-44,634
| -50% | -$930K | ﹤0.01% | 4392 |
|
|
2018
Q3 | $2.24M | Sell |
90,154
-10,160
| -10% | -$250K | ﹤0.01% | 3916 |
|
|
2018
Q2 | $2.42M | Buy |
100,314
+93,845
| +1,451% | +$2.53M | ﹤0.01% | 3889 |
|
|
2018
Q1 | $188K | Buy |
6,469
+6,269
| +3,135% | +$178K | ﹤0.01% | 5494 |
|
|
2017
Q4 | $5K | Buy |
+200
| New | +$5.05K | ﹤0.01% | 6332 |
|
|
2017
Q2 | – | Sell |
-100
| Closed | -$2K | – | 6592 |
|
|
2017
Q1 | $2K | Buy |
+100
| New | +$2.3K | ﹤0.01% | 6451 |
|
Other funds holding CNCR
Morgan Stanley's CNCR Position: Q2 2025 in Review
Morgan Stanley sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2025, closing a stake of 1,448 shares — an estimated $13.7K sold.
Morgan Stanley first reported a position in CNCR in Q1 2017 and held it in 31 quarters. The position peaked at $2.42M in Q2 2018. 1 fund tracked by Wall St. Rank holds CNCR as of Q2 2025.
- Morgan Stanley reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2025 after selling out during the quarter.
- Morgan Stanley sold 1,448 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2025, an estimated $13.7K.
- Morgan Stanley first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q1 2017 and held it in 31 quarters.
- Morgan Stanley's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $2.42M in Q2 2018.
- 1 fund tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2025.
Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.